Tag: ngs oncology market research

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

NGS Oncology Market Size Outlook: How Fast Will Revenue Grow Through 2030?

The market for next-generation sequencing in oncology has experienced notable expansion. Projections indicate a progression from $19.33 billion in 2025 to $21.54 billion in 2026, reflecting a compound annual growth rate of 11.4%. Key factors driving this growth during the earlier period include reduced costs associated with sequencing technologies, an increase in cancer incidence worldwide, enhanced financial support for cancer research, the early integration of precision medicine treatments, and the advancement of genomic research programs.

The NGS oncology sector is poised for substantial expansion in the coming years, projecting a market value of $32.87 billion by 2030, fueled by an 11.2% compound annual growth rate. This anticipated growth trajectory is predominantly driven by the increasing implementation of precision oncology initiatives, a rising consumer desire for individualized cancer therapies, a greater number of NGS-based diagnostic approvals, improvements in bioinformatics analysis capabilities, and the incorporation of NGS into established clinical protocols. Key developments anticipated during this forecast period encompass the broader application of comprehensive tumor profiling, a surge in the utilization of liquid biopsy NGS, enhanced clinical relevance of multi-gene diagnostic panels, the integration of next-generation sequencing into standard oncological diagnostic practices, and a growing need for expedited sequencing processes.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

NGS Oncology Market Development Factors: Which Trends Are Supporting Demand?

The escalating incidence of cancer is anticipated to be a primary catalyst for the expansion of the NGS oncology sector in the future. Characterized by the unchecked proliferation of aberrant cells that can infiltrate other bodily regions and interfere with essential physiological processes, cancer’s increasing occurrence is largely attributable to an aging demographic, global population expansion, and heightened exposure to detrimental factors such as tobacco and alcohol consumption, obesity, and environmental pollutants. By facilitating the early identification, accurate diagnosis, and individualized therapeutic strategies through comprehensive genetic analysis of tumors, NGS oncology plays a crucial role in public health initiatives and patient management. Indicatively, published statistics from the American Cancer Society in January 2024 suggest that the United States anticipates 2,001,140 new cancer diagnoses and 611,720 fatalities in 2024, a slight uptick from the estimated 1,958,310 cases and 609,820 deaths recorded in 2023, underscoring the direct correlation between the growing burden of cancer and the advancement of the NGS oncology market.

NGS Oncology Market Segment Landscape: Which Areas Lead Market Development?

The ngs oncology market covered in this report is segmented –

1) By Sequencing Technology: Targeted Sequencing, Genomics, Transcriptomics, Epigenomics

2) By Offering: Platform, Kits, Services

3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis

4) By Application: Genetic Screening, Hereditary Genetic Testing, Hematological Malignancies, Solid Tumors, Other Applications

5) By End User: Hospitals And Clinics, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Targeted Sequencing: Whole Exome Sequencing (WES), Amplicon-Based Sequencing, Hybridization-Based Sequencing

2) By Genomics: Whole Genome Sequencing (WGS), Structural Variant Detection, Copy Number Variation (CNV) Analysis

3) By Transcriptomics: RNA Sequencing, Single-Cell Transcriptomics, Non-Coding RNA Analysis

4) By Epigenomics: DNA Methylation Sequencing, Chromatin Immunoprecipitation Sequencing, Histone Modification Analysis

NGS Oncology Market Transformation Trends: Which Innovations Are Driving Change?

The leading entities within the NGS oncology sector are actively pursuing the creation of novel approaches, specifically liquid biopsy research assays, to facilitate non-intrusive, continuous cancer detection and surveillance via the examination of circulating tumor DNA. Fundamentally, a liquid biopsy research assay constitutes a diagnostic process that scrutinizes bodily fluids, for example, blood, in order to identify genetic alterations or alternative molecular indicators linked to malignancy, thereby permitting cancer identification and observation without surgical intervention. As an illustration, in August 2024, Illumina Inc., a prominent American biotechnology firm renowned for its expertise in next-generation sequencing (NGS) technologies, augmented its oncology offerings designed for users of its NovaSeq X Series. This expansion includes the recently validated, high-capacity TruSight Oncology 500 (TSO 500 HT) and the revised TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These advanced assays empower laboratories to expand their oncology research capacities for both tissue and liquid biopsy specimens, characterized by heightened sequencing effectiveness, diminished processing durations, and the unprecedented possibility of handling greater quantities of samples on the NovaSeq X Series.

NGS Oncology Market Industry Leaders And Market Competition

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Access The Complete NGS Oncology Market Report:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

NGS Oncology Market Geographic Landscape: Which Region Dominates Industry Growth?

North Americawas the largest region in the NGS oncology market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the ngs oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, How Much Growth In Market Size Is Expected For The NGS Oncology Market?

The ngs oncology market size has experienced substantial growth in recent years. It is projected to expand from $19.33 billion in 2025 to $21.54 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.4%. This historic growth can be attributed to several factors including decreasing sequencing costs, a rise in global cancer prevalence, increased funding for oncology research, the early adoption of targeted therapies, and the growth of genomic research initiatives.

The ngs oncology market size is projected to experience substantial growth in the next few years. It is expected to reach $32.87 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.2%. The expansion during the forecast period is attributable to the broadening of precision oncology programs, a rising demand for personalized cancer treatment, an increase in approvals for ngs-based diagnostics, advancements in bioinformatics analytics, and the integration of ngs into clinical guidelines. Major developments anticipated in this period include the wider use of comprehensive tumor profiling, the increasing adoption of liquid biopsy NGS, an enhanced clinical utility of multi-gene panels, the incorporation of NGS into routine oncology diagnostics, and a growing demand for faster turnaround sequencing workflows.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

Which Growth Drivers Are Expected To Support The NGS Oncology Market Forward?

An increasing incidence of cancer is anticipated to fuel the expansion of the NGS oncology market. This disease involves the uncontrolled growth of abnormal cells that can infiltrate various body parts, disrupting normal physiological functions. This surge in cancer cases is largely attributed to an aging populace, overall population expansion, and heightened exposure to risk factors including tobacco consumption, alcohol intake, obesity, and atmospheric pollution. NGS oncology plays a crucial role in public health and patient care by facilitating early detection, accurate diagnosis, and tailored treatment through comprehensive genetic profiling of tumors. For example, data released by the American Cancer Society, a US-based non-profit organization, in January 2024 indicates that the United States is expected to record 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, an increase from 1,958,310 cases and 609,820 deaths in 2023. Consequently, the increasing occurrence of cancer is a key factor propelling the expansion of the NGS oncology market.

How Is The NGS Oncology Market Structured Across Different Market Segments?

The ngs oncology market covered in this report is segmented –

1) By Sequencing Technology: Targeted Sequencing, Genomics, Transcriptomics, Epigenomics

2) By Offering: Platform, Kits, Services

3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis

4) By Application: Genetic Screening, Hereditary Genetic Testing, Hematological Malignancies, Solid Tumors, Other Applications

5) By End User: Hospitals And Clinics, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Targeted Sequencing: Whole Exome Sequencing (WES), Amplicon-Based Sequencing, Hybridization-Based Sequencing

2) By Genomics: Whole Genome Sequencing (WGS), Structural Variant Detection, Copy Number Variation (CNV) Analysis

3) By Transcriptomics: RNA Sequencing, Single-Cell Transcriptomics, Non-Coding RNA Analysis

4) By Epigenomics: DNA Methylation Sequencing, Chromatin Immunoprecipitation Sequencing, Histone Modification Analysis

Which Trends Are Guiding The Development Of The NGS Oncology Market?

Leading companies in the next-generation sequencing data analysis market are concentrating on developing advanced secondary analysis bioinformatics software. Their aim is to enable quicker and more precise identification of genetic variants for both research and clinical applications. Secondary analysis bioinformatics software is engineered to process raw next-generation sequencing (NGS) data, converting it into interpretable formats such as variant call files (VCF), which provide detailed genetic variant information. This software significantly streamlines the analysis of NGS data for research and clinical purposes. For example, in January 2024, QIAGEN Digital Insights, a US-based bioinformatics entity of QIAGEN, unveiled the QIAGEN CLC Genomics Workbench Premium with LightSpeed technology. This software enhances next-generation sequencing (NGS) for somatic cancer analysis and swiftly processes whole genome sequencing (WGS) samples. Using LightSpeed technology, which efficiently transforms raw FASTQ data into interpretable formats, it can analyze 34x human genomes in 25 minutes and 50x exomes in 90 seconds. With expenses as low as $1 for genomes and a few cents for exomes when utilizing cloud infrastructure, it represents an economical solution for high-throughput laboratories. The program functions on standard hardware or cloud platforms, offering flexibility and exceptional accuracy, making it well-suited for clinical applications while also minimizing its carbon footprint.

Which Organizations Are Involved In The NGS Oncology Market?

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Access The Complete NGS Oncology Market Report:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Which Region Holds The Largest Share In The NGS Oncology Market?

North America was the largest region in the NGS oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngs oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access NGS Oncology Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=24337&type=smp

Browse Through More Reports Similar to the Global NGS Oncology Market 2026, By The Business Research Company

Ngs Based Rna Sequencing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/ngs-based-rna-sequencing-global-market-report

Prenatal Dna Sequencing Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report

Next Generation Firewall Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/next-generation-firewall-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The NGS Oncology Market In 2026, And How Will Its Value Evolve By 2030?

The ngs oncology market has experienced significant expansion recently. This market is projected to expand from $19.33 billion in 2025 to $21.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.4%. Factors contributing to this historical growth include declining sequencing costs, rising global cancer prevalence, increased oncology research funding, early adoption of targeted therapies, and the growth of genomic research initiatives.

The ngs oncology market is projected for substantial expansion in the coming years. It is anticipated to reach $32.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.2%. This increase during the projected period stems from factors such as the expansion of precision oncology programs, rising demand for personalized cancer treatments, a surge in approvals for ngs-based diagnostics, progress in bioinformatics analytics, and the incorporation of ngs into standard clinical guidelines. Key trends expected over the forecast horizon encompass broader comprehensive tumor profiling, greater uptake of liquid biopsy NGS, enhanced clinical applicability of multi-gene panels, the incorporation of NGS into everyday oncology diagnostics, and an increasing need for quicker sequencing workflows.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

What Significant Factors Are Influencing The NGS Oncology Market Expansion?

The increasing incidence of cancer is anticipated to drive the expansion of the NGS oncology market in the future. Cancer is characterized by the uncontrolled proliferation of anomalous cells, which can spread to other bodily regions and disrupt regular physiological processes. This increase in cancer cases is largely attributed to an aging populace, overall population expansion, and greater exposure to risk factors such as tobacco use, alcohol consumption, obesity, and air pollution. NGS oncology contributes to public health and enhances patient care through facilitating early discovery, accurate diagnosis, and tailored treatment strategies via comprehensive genetic profiling of tumors. For example, data released in January 2024 by the American Cancer Society, a US-based non-profit organization, indicates that the United States is forecast to record 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, a rise from 1,958,310 cases and 609,820 deaths in 2023. Consequently, the growing occurrence of cancer is a key factor propelling the expansion of the NGS oncology market.

Which Segment Classifications Are Used In The NGS Oncology Market Segment Analysis?

The ngs oncology market covered in this report is segmented –

1) By Sequencing Technology: Targeted Sequencing, Genomics, Transcriptomics, Epigenomics

2) By Offering: Platform, Kits, Services

3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis

4) By Application: Genetic Screening, Hereditary Genetic Testing, Hematological Malignancies, Solid Tumors, Other Applications

5) By End User: Hospitals And Clinics, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Targeted Sequencing: Whole Exome Sequencing (WES), Amplicon-Based Sequencing, Hybridization-Based Sequencing

2) By Genomics: Whole Genome Sequencing (WGS), Structural Variant Detection, Copy Number Variation (CNV) Analysis

3) By Transcriptomics: RNA Sequencing, Single-Cell Transcriptomics, Non-Coding RNA Analysis

4) By Epigenomics: DNA Methylation Sequencing, Chromatin Immunoprecipitation Sequencing, Histone Modification Analysis

What Trends Are Affecting The Direction Of The NGS Oncology Market?

Leading firms within the NGS oncology market are concentrating on creating advanced solutions, including liquid biopsy research assays, to facilitate non-invasive, real-time cancer identification and tracking by analyzing circulating tumor DNA. This type of diagnostic test examines biological fluids, like blood, to identify genetic alterations or other molecular indicators linked to cancer, thereby supporting non-invasive cancer detection and monitoring. For example, in August 2024, Illumina Inc., a US-based biotechnology company focused on next-generation sequencing (NGS) technology, broadened its oncology offerings for users of its NovaSeq X Series. The company now provides the recently validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the upgraded TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These improved assays empower laboratories to expand their oncology research capacities for both tissue and liquid biopsy samples, offering better sequencing efficiency, shorter run durations, and the novel capability to process greater sample volumes on the NovaSeq X Series.

Which Firms Are Contributing To The NGS Oncology Market Ecosystem?

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Get The Full NGS Oncology Market Report:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Which Region Holds The Highest Market Share In The NGS Oncology Market?

North America was the largest region in the NGS oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngs oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized NGS Oncology Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Browse Through More Reports Similar to the Global NGS Oncology Market 2026, By The Business Research Company

Ngs Based Rna Sequencing Market Report 2026

https://www.thebusinessresearchcompany.com/report/ngs-based-rna-sequencing-global-market-report

Prenatal Dna Sequencing Market Report

https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report

Next Generation Firewall Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-firewall-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The NGS Oncology Market From 2026 To 2030?

The ngs oncology market has experienced substantial expansion recently. Its size is projected to increase from $19.33 billion in 2025 to $21.54 billion in 2026, at a compound annual growth rate (CAGR) of 11.4%. The observed growth in the historic period can be attributed to factors such as declining sequencing costs, rising global cancer prevalence, increased oncology research funding, early adoption of targeted therapies, and the growth of genomic research initiatives.

The ngs oncology market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $32.87 billion by 2030, driven by a compound annual growth rate (CAGR) of 11.2%. This growth throughout the forecast period stems from factors such as the proliferation of precision oncology initiatives, the increasing need for individualized cancer therapies, a rise in approvals for ngs-based diagnostic tools, progress in bioinformatics analytics, and the incorporation of ngs into established clinical protocols. Key developments expected during this timeframe encompass the broadening scope of comprehensive tumor profiling, the growing acceptance of liquid biopsy NGS, enhanced clinical usefulness of multi-gene panels, the incorporation of NGS into standard oncology diagnostic practices, and an escalating requirement for more expeditious sequencing workflows.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

What Major Drivers Are Influencing Demand In The NGS Oncology Market?

The increasing occurrence of cancer is projected to stimulate expansion in the NGS oncology market in the coming years. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells that can infiltrate other bodily regions, disrupting regular physiological operations. This rise in cancer cases is largely attributed to an aging global population, overall population expansion, and heightened exposure to risk factors like tobacco consumption, alcohol intake, excess weight, and atmospheric pollution. NGS oncology contributes significantly to public health and patient well-being by facilitating prompt detection, accurate diagnosis, and tailored treatment plans through comprehensive genetic analysis of tumors. For example, in January 2024, data released by the American Cancer Society, a US-based non-profit organization, indicated that the United States is anticipated to record 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, a notable increase from 1,958,310 cases and 609,820 deaths in 2023. Consequently, the growing prevalence of cancer is propelling the development of the NGS oncology market.

Which Segments Are Included In The Analysis Of The NGS Oncology Market?

The ngs oncology market covered in this report is segmented –

1) By Sequencing Technology: Targeted Sequencing, Genomics, Transcriptomics, Epigenomics

2) By Offering: Platform, Kits, Services

3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis

4) By Application: Genetic Screening, Hereditary Genetic Testing, Hematological Malignancies, Solid Tumors, Other Applications

5) By End User: Hospitals And Clinics, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Targeted Sequencing: Whole Exome Sequencing (WES), Amplicon-Based Sequencing, Hybridization-Based Sequencing

2) By Genomics: Whole Genome Sequencing (WGS), Structural Variant Detection, Copy Number Variation (CNV) Analysis

3) By Transcriptomics: RNA Sequencing, Single-Cell Transcriptomics, Non-Coding RNA Analysis

4) By Epigenomics: DNA Methylation Sequencing, Chromatin Immunoprecipitation Sequencing, Histone Modification Analysis

How Are Trends Transforming The NGS Oncology Market Landscape?

Leading companies in the NGS oncology market are dedicated to developing innovative solutions, such as liquid biopsy research assays, to facilitate non-invasive, real-time cancer detection and monitoring by analyzing circulating tumor DNA. These diagnostic tests examine biological fluids, including blood, to identify genetic mutations or other molecular markers associated with cancer. For instance, in August 2024, Illumina Inc., a US-based biotechnology company specializing in next-generation sequencing (NGS) technology, broadened its oncology portfolio for NovaSeq X Series users. The company now provides the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These enhanced assays empower laboratories to expand oncology research capabilities for both tissue and liquid biopsy samples, offering improved sequencing efficiency, shorter run times, and the new ability to process larger sample volumes on the NovaSeq X Series.

Which Key Industry Participants Are Active In The NGS Oncology Market?

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Read the full ngs oncology market report here:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The NGS Oncology Market?

North America was the largest region in the NGS oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngs oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored NGS Oncology Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24337&type=smp

Browse Through More Reports Similar to the Global NGS Oncology Market 2026, By The Business Research Company

Ngs Based Rna Sequencing Global Market Report

https://www.thebusinessresearchcompany.com/report/ngs-based-rna-sequencing-global-market-report

Prenatal Dna Sequencing Global Market Report

https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report

Next Generation Firewall Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-firewall-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the ngs oncology market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the NGS Oncology Market in 2030?

The ngs oncology market has seen significant and rapid expansion in its size over recent years. It is projected to expand from $19.33 billion in 2025 to $21.54 billion in 2026, at a compound annual growth rate (CAGR) of 11.4%. This historical growth can be ascribed to elements such as declining sequencing costs, rising global cancer prevalence, increased oncology research funding, early adoption of targeted therapies, and the proliferation of genomic research initiatives.

The ngs oncology market is projected to experience substantial growth over the next few years, with its size expected to reach $32.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.2%. This projected expansion during the forecast period is largely fueled by the increasing development of precision oncology programs, a rising need for individualized cancer treatments, the growing number of approvals for ngs-based diagnostic tools, continuous innovations in bioinformatics analytics, and the incorporation of ngs into standard clinical guidelines. Significant trends for this period encompass the broader adoption of comprehensive tumor profiling, the increasing use of liquid biopsy NGS, the enhanced clinical value of multi-gene panels, the embedding of NGS in routine oncology diagnostic processes, and the escalating demand for more rapid sequencing workflows.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24337&type=smp

What Drivers Are Influencing Production Trends In The NGS Oncology Market?

The escalating incidence of cancer is anticipated to fuel the expansion of the NGS oncology market in the future. Cancer is a condition characterized by the unrestrained proliferation of abnormal cells, which can invade other bodily regions and disrupt normal physiological functions. The rise in cancer cases is primarily driven by demographic shifts, including an aging population and overall population growth, alongside increased exposure to risk factors such as tobacco use, alcohol consumption, obesity, and air pollution. NGS oncology supports public health and patient management by enabling prompt detection, precise diagnosis, and personalized treatment through comprehensive genetic analysis of tumors. For instance, in January 2024, figures released by the American Cancer Society, a US-based non-profit organization, project that the United States will record 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, an increase compared to 1,958,310 cases and 609,820 deaths in 2023. Consequently, the increasing prevalence of cancer is a key driver for the growth of the NGS oncology market.

Which Segments Are Gaining Traction In The NGS Oncology Market?

The ngs oncology market covered in this report is segmented –

1) By Sequencing Technology: Targeted Sequencing, Genomics, Transcriptomics, Epigenomics

2) By Offering: Platform, Kits, Services

3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis

4) By Application: Genetic Screening, Hereditary Genetic Testing, Hematological Malignancies, Solid Tumors, Other Applications

5) By End User: Hospitals And Clinics, Clinical Research Organizations (CROs), Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Other End Users

Subsegments:

1) By Targeted Sequencing: Whole Exome Sequencing (WES), Amplicon-Based Sequencing, Hybridization-Based Sequencing

2) By Genomics: Whole Genome Sequencing (WGS), Structural Variant Detection, Copy Number Variation (CNV) Analysis

3) By Transcriptomics: RNA Sequencing, Single-Cell Transcriptomics, Non-Coding RNA Analysis

4) By Epigenomics: DNA Methylation Sequencing, Chromatin Immunoprecipitation Sequencing, Histone Modification Analysis

Which Trends Are Shaping Activity Within The NGS Oncology Market?

Major companies operating in the NGS oncology market are focusing on developing innovative solutions, such as liquid biopsy research assays, to enable non-invasive, real-time cancer detection and monitoring through the analysis of circulating tumor DNA. A liquid biopsy research assay is a diagnostic test that analyzes biological fluids, such as blood, to detect genetic mutations or other molecular markers associated with cancer, allowing for non-invasive cancer detection and monitoring. For instance, in August 2024, Illumina Inc., a US-based biotechnology company specializing in next-generation sequencing (NGS) technology, expanded its oncology portfolio for NovaSeq X Series users. The company now offers the newly validated high-throughput TruSight Oncology 500 (TSO 500 HT) and the updated TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) liquid biopsy research assay. These enhanced assays enable laboratories to broaden oncology research capabilities for both tissue and liquid biopsy samples, featuring improved sequencing efficiency, reduced run times, and the ability to process larger sample volumes on the NovaSeq X Series for the first time.

Who Are The Prominent Global Companies Shaping The NGS Oncology Market Landscape?

Major companies operating in the ngs oncology market are Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Eurofins Scientific SE, Illumina Inc., Qiagen N.V., Tecan Trading AG, Myriad Genetics, Takara Bio Inc., Beijing Genomics Institute (BGI), Caris Life Sciences, Foundation Medicine, Paradigm Diagnostics, Pacific Bioscience, Horizon Discovery Group plc , Creative-Biolabs, Xcelris Labs Ltd., Partek Inc., 4baseCare, SciGenom Labs Pvt. Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/ngs-oncology-global-market-report

Which Region Is Projected To Lead The NGS Oncology Market During The Forecast Period?

North America was the largest region in the NGS oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ngs oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized NGS Oncology Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24337&type=smp

Browse Through More Reports Similar to the Global NGS Oncology Market 2026, By The Business Research Company

Oncology Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Community Oncology Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model